Feedback / Questions
ELI-002 7P - Elicio Therap
https://www.globenewswire.com/news-release/2025/11/07/3183698/0/en/Elicio-Therapeutics-Reports-Robust-Cytolytic-mKRAS-Specific-T-Cell-Responses-Across-Diverse-Patient-HLA-in-Ongoing-Phase-2-AMPLIFY-7P-Trial-of-ELI-002-7P-and-New-ELI-004-Preclinica.html
Nov 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next